SEC Form 4 · accession 0001209191-16-129548

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 22, 2016

Accepted (ET)

Jun 24, 2016 · 4:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 22, 2016	M	5,130	$35.35	A	273,355	D
Common Stock^F2,F3	Jun 22, 2016	S	2,430	$85.84	D	270,925	D
Common Stock^F2,F4	Jun 22, 2016	S	1,500	$86.54	D	269,425	D
Common Stock^F2,F5	Jun 22, 2016	S	500	$87.81	D	268,925	D
Common Stock^F2,F6	Jun 22, 2016	S	700	$88.58	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	122,700	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$35.35	Jun 22, 2016	M	5,130	D	—	Jul 19, 2016	Common Stock	5,130	10,270	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $85.84 (range $85.15 to $86.12).
F4Open market sales reported on this line occurred at a weighted average price of $86.54 (range $86.16 to $87.15).
F5Open market sales reported on this line occurred at a weighted average price of $87.81 (range $87.28 to $88.21).
F6Open market sales reported on this line occurred at a weighted average price of $88.58 (range $88.29 to $88.83).
F7Fully vested.